CARGO Therapeutics, Inc.

Clinical-stage biotechnology company focused on designing, engineering, and developing next-generation cell (CAR T) therapies for cancer patients; pipeline includes CRG-023, a tri-specific CAR T targeting CD19, CD20 and CD22.